U.S. officials keep close watch on the ‘delta plus’ Covid mutation as it spreads in the U.K.

Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention, testifies before a Senate Health, Education, Labor and Pensions Committee hearing at the U.S. Capitol on May 11, 2021. Jim Lo Scalzo | Pool | Reuters U.S. health officials are keeping a close eye on an emerging Covid-19 subvariant, dubbed “delta plus,” that …

U.S. surgeon general says ‘quite reasonable’ for Pfizer, Moderna recipients to get same booster

U.S. Surgeon General Dr. Vivek Murthy told CNBC on Friday that Americans should consider their primary vaccine series when deciding on a booster, noting that all three available are safe and effective. The Centers for Disease Control and Prevention late Thursday approved the distribution of booster doses of Moderna‘s Covid vaccine for adults most at …

5 things to know before the stock market opens Friday

Here are the most important news, trends and analysis that investors need to start their trading day: 1. Stock futures mixed after S&P 500’s record close Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., October 20, 2021. Brendan McDermid | Reuters U.S. stock futures were mixed …

CDC panel unanimously endorses Moderna and J&J Covid boosters, sending to director for final approval

An influential Centers for Disease Control and Prevention advisory committee on Thursday unanimously recommended boosters of Moderna and Johnson & Johnson‘s Covid-19 vaccines, sending it to CDC Director Dr. Rochelle Walensky for final approval. The agency’s Advisory Committee on Immunization Practices meeting recommended the Moderna booster for elderly people and at-risk adults six months after …

CDC says these are the most common side effects people report after getting Moderna, J&J boosters

A healthcare clinician prepares a dose of the Johnson & Johnson vaccine for the coronavirus disease (COVID-19) for a commuter during the opening of MTA’s public vaccination program at the 179th Street subway station in the Queens borough of New York City, New York, U.S., May 12, 2021. Shannon Stapleton | Reuters The Centers for …

Watch live: CDC panel to vote on Moderna and J&J Covid booster shots

[The stream is slated to start at 10 a.m. ET. Please refresh the page if you do not see a player above at that time.] A key Centers for Disease Control and Prevention advisory committee is meeting Thursday to discuss booster shots of Moderna and Johnson & Johnson‘s vaccine as well as whether people can …

How rising UK Covid cases could be ‘a compelling argument for boosters’

Former Obama White House policy director Dr. Kavita Patel explained why the surging number of Covid cases in the United Kingdom could be a compelling argument for booster shots.  “What’s happening is … this real world experiment where the efficacy of AstraZeneca is decreasing, and they haven’t rolled out their boosters,” Patel said during a …

Stocks making the biggest moves midday: Ulta, ProShares Bitcoin Strategy ETF, ChargePoint and more

Fans gather at local Ulta Beauty in Houston to greet Kylie Jenner at the launch of her cosmetics line on November 18, 2018 in Houston, Texas. Rick Kern | Getty Images Check out the companies making headlines in midday trading. Ulta — Shares of the cosmetics store dropped more than 5% after the company released …

5 things to know before the stock market opens Tuesday

Here are the most important news, trends and analysis that investors need to start their trading day: 1. Stock futures jump after S&P 500, Nasdaq log 4-day win streaks Traders work on the floor of the New York Stock Exchange (NYSE), October 12, 2021. Brendan McDermid | Reuters 2. Dow stocks J&J and P&G each …

J&J Covid vaccine adds $502 million to third-quarter sales

Johnson & Johnson said it sold $502 million of its Covid-19 vaccine in the third quarter, in its earnings report Tuesday that beat Wall Street’s profit expectations. Here’s how J&J did compared with what Wall Street expected, according to average estimates compiled by Refinitiv: Adjusted EPS: $2.60 per share vs $2.35 expected. Revenue: $23.34 billion …